Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) has completed a shares-for-debt settlement, issuing common shares to extinguish $192,300 in outstanding indebtedness. The transaction, first announced on September 24, 2026, was concluded at a deemed price of $0.155 per common share and has received final acceptance from the TSX Venture Exchange. The settlement allows the Calgary-based pharmaceutical developer to conserve cash as it continues building its barium and iodine contrast media business.

Key Points

  • Voyageur Pharmaceuticals Ltd. (TSXV: VM / OTC Pink: VYYRF)
  • Completed shares-for-debt settlement extinguishing $192,300 in total outstanding indebtedness
  • 1,240,644 common shares issued in aggregate at a deemed price of $0.155 per share; shares subject to a four-month-and-one-day hold period
  • Investors may be watching how cash preservation supports the company's ongoing product development activities

Debt Settlement Split Between Officer and Outside Creditors

Of the $192,300 total debt settled, $52,300 was owed to a company officer for accrued consulting fees, settled through the issuance of 337,419 common shares. The remaining $140,000 was owed to certain other creditors and was settled through the issuance of an aggregate of 903,225 common shares. The company stated that the transaction was structured to preserve its cash position, a consideration that may be relevant to investors evaluating Voyageur's current liquidity management approach.

Related-Party Transaction Exemptions Applied Under MI 61-101

Because the officer involved is a related party, the share issuance to settle accrued consulting fees constitutes a related-party transaction under Multilateral Instrument 61-101 — Protection of Minority Security Holders in Special Transactions. The company relied on exemptions under sections 5.5(a) and 5.7(1)(a) of MI 61-101, citing that neither the fair market value of the debt settled with the officer nor the fair market value of the shares issued to the officer exceeded 25% of the company's market capitalisation. The TSX Venture Exchange has granted final acceptance of all issuances.

Voyageur's Barium Contrast Media Strategy and Frances Creek Asset

Voyageur is a Canadian developer focused on pharmaceutical-grade barium and iodine contrast media for medical imaging. The company holds five barium contrast products with Health Canada licences and owns a 100% interest in the Frances Creek barium sulfate project in British Columbia. Management describes the Frances Creek resource as a rare, high-grade mineral deposit that it believes could deliver superior imaging quality compared with synthetically produced barium sulfate. The company's stated long-term goal is to become the first vertically integrated operator in the radiology contrast media market, from raw material sourcing through to final product.